Catalyst Pharmaceuticals (CPRX) EBT (2010 - 2026)

Catalyst Pharmaceuticals has reported EBT for 17 years, with the latest figure at $84.2 million in Q1 2026.

• For the quarter ending Q1 2026, EBT rose 18.16% year-over-year to $84.2 million; the trailing twelve-month figure through Mar 2026 stood at $296.5 million (up 14.7% YoY), and the FY2025 full-year result was $283.5 million, up 31.1% from the prior year.
• EBT for Q1 2026 stood at $84.2 million, up from $71.9 million in the prior quarter.
• The five-year high for EBT was $84.2 million in Q1 2026, with the low at -$38.0 million in Q3 2023.
• Historically, EBT has averaged $46.1 million across 5 years, with a median of $48.5 million in 2023.
• Annual changes were most pronounced in 2023 — EBT tumbled 246.2% — and 2024, when it jumped 250.46%.
• Catalyst Pharmaceuticals' EBT stood at $33.0 million in 2022, then jumped by 41.5% to $46.7 million in 2023, then surged by 58.82% to $74.2 million in 2024, then decreased by 3.07% to $71.9 million in 2025, then climbed by 17.15% to $84.2 million in 2026.
• The last three EBT figures came in at $84.2 million (Q1 2026), $71.9 million (Q4 2025), and $71.0 million (Q3 2025), per Business Quant data.